SecBot SecBot
8-K ·Filed Nov 9, 2026

CABA

Cabaletta Bio, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed7d 20h ago SEC0001759138-26-000050
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The clinical data strengthens the case for rese-cel's efficacy and safety across multiple autoimmune indications. Key catalysts to watch: topline registrational DM/ASyS results in 2H27 and BLA submission in 1Q28. Monitor enrollment progress in the registrational SSc-ILD cohort and go-forward strategy for the preconditioning-free approach in 1H27.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.50
T+0 close · Nov 9, 2026 · via day close
Latest settled
−26.00%
T+5 · $1.11
Vs SPY
−24.31%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.50entry
  2. T+1 · 7d ago −3.33%α −2.97% · $1.45
  3. T+5 · 20h ago −26.00%α −24.31% · $1.11
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio presented new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026, showing 100% of dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses through one year, 100% of lupus nephritis patients with repeat biopsy achieved DORIS remission and histologic response, and 71% of systemic sclerosis patients achieved rCRISS-50 at one year with a 9% mean FVC improvement in ILD patients. The company also disclosed plans for a BLA submission in myositis in 1Q28 and topline results from the registrational DM/ASyS cohort in 2H27.

Key Facts

  • 100% (6/6) of adult DM patients maintained immunomodulator-free moderate-to-major TIS response through one year; 83% (5/6) achieved this at Week 16
  • 100% (5/5) of LN patients with repeat kidney biopsy achieved immunomodulator-free DORIS remission and histologic response or remission
  • 71% (5/7) of SSc patients achieved immunomodulator-free rCRISS-50 at one year; 5 ILD patients showed 9% mean FVC improvement
  • 94% (67/71) of patients had no or Grade 1 CRS; 96% (68/71) had no ICANS; no IEC-HS reported
  • Company plans to report topline registrational DM/ASyS results in 2H27 and submit BLA for myositis in 1Q28
  • Operational runway into 1Q28 enables all anticipated milestones

Financial Impact

No financial data provided; clinical data supports advancement of registrational cohorts and BLA timeline

Risk Factors

  • Phase 1/2 data may not be predictive of registrational trial results
  • BLA submission and approval timelines are subject to regulatory review and potential delays
  • Competition from other CAR-T and autoimmune therapies could impact commercial adoption
  • Manufacturing scale-up and automation (Cellares) carry execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759138-26-000050
Document: caba-20261109.htm0001759138-26-000050
Document: caba-ex99_1.htm0001759138-26-000050
Document: 0001759138-26-000050-index-headers.html0001759138-26-000050
Document: 0001759138-26-000050-index.html0001759138-26-000050
Document: 0001759138-26-000050.txt0001759138-26-000050

Track record

29 reports on CABA

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026